Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2021-10-28 Regulatory Filings
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
Consent letter of issuer's legal counsel.pdf
Regulatory Filings
2021-10-28 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the CEO of PsyBio Therapeutics will participate in a panel discussion at a conference. It contains no financial data, no regulatory filings, no voting results, no management or board changes, no earnings or annual report information. It is a corporate announcement about an event involving the company's CEO. The document length is short (3814 characters) and it is clearly not a report or financial filing. Therefore, it does not fit into any of the specific financial or regulatory filing categories. The best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other categories.
2021-10-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics Corp.'s subordinate voting shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC). It discusses the implications of this eligibility for liquidity and trading but does not contain any financial statements, detailed financial results, or regulatory filings. There is no indication of an annual or quarterly report, audit report, management changes, or other specific filings. The content is an announcement about a capital market operational update related to share trading and settlement. This fits best under Capital/Financing Update (CAP) as it relates to the company's capital market activities and share trading facilitation. The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Confidence is high due to clear focus on DTC eligibility and trading liquidity.
2021-10-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics has successfully demonstrated commercial scale manufacturing feasibility for one of its therapeutic candidates. It discusses the company's progress, technology scale-up, and future plans for manufacturing and clinical development. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about operational progress rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate news announcement about manufacturing capability and development progress, which aligns best with a Regulatory Filings (RNS) classification as a general regulatory announcement or corporate update that does not fit other specific categories.
2021-10-07 English
News release - English.pdf
Regulatory Filings
2021-09-23 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the company's participation in upcoming investor conferences in September 2021. It includes details about the events, dates, and contact information for scheduling meetings. There is no financial data, no report attached or referenced as being published, no voting results, no management changes, no legal proceedings, no capital updates, and no earnings or interim report data. The document is essentially a corporate announcement about investor relations activities and conference participation. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and corporate news that do not fit other specific categories.
2021-09-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.